NYSE:USNA - USANA Health Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$124.1250 +2.86 (+2.36 %)
(As of 12/12/2018 12:37 PM ET)
Previous Close$121.27
Today's Range$121.51 - $124.82
52-Week Range$69.55 - $137.95
Volume53,168 shs
Average Volume159,632 shs
Market Capitalization$2.88 billion
P/E Ratio30.57
Dividend YieldN/A
Beta0.79
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensé—beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medicinals & botanicals
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNYSE:USNA
Previous Symbol
CUSIP90328M10
Phone801-954-7100

Debt

Debt-to-Equity RatioN/A
Current Ratio2.84
Quick Ratio2.31

Price-To-Earnings

Trailing P/E Ratio30.57
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.05 billion
Price / Sales2.84
Cash Flow$5.0131 per share
Price / Cash Flow24.76
Book Value$15.14 per share
Price / Book8.20

Profitability

EPS (Most Recent Fiscal Year)$4.06
Net Income$62.53 million
Net Margins7.57%
Return on Equity29.67%
Return on Assets21.58%

Miscellaneous

Employees1,810
Outstanding Shares23,980,000
Market Cap$2.88 billion
OptionableOptionable

USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its board has initiated a share buyback plan on Tuesday, October 23rd 2018, which authorizes the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 5.9% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's management believes its stock is undervalued.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings data on Tuesday, October, 23rd. The company reported $1.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.14. The business earned $296.80 million during the quarter, compared to analysts' expectations of $289.54 million. USANA Health Sciences had a return on equity of 29.67% and a net margin of 7.57%. The firm's quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the company earned $1.03 earnings per share. View USANA Health Sciences' Earnings History.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for USANA Health Sciences.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences updated its FY18 earnings guidance on Tuesday, October, 23rd. The company provided EPS guidance of $5.00-5.15 for the period, compared to the Thomson Reuters consensus estimate of $4.95. The company issued revenue guidance of $1.185-1.20 billion, compared to the consensus revenue estimate of $1.19 billion.USANA Health Sciences also updated its FY 2018 guidance to $1.10-1.10 EPS.

What price target have analysts set for USNA?

2 brokers have issued 1-year price targets for USANA Health Sciences' shares. Their predictions range from $135.00 to $135.00. On average, they anticipate USANA Health Sciences' stock price to reach $135.00 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

What is the consensus analysts' recommendation for USANA Health Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for USANA Health Sciences.

Has USANA Health Sciences been receiving favorable news coverage?

Media stories about USNA stock have been trending positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. USANA Health Sciences earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of USANA Health Sciences' key competitors?

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the folowing people:
  • Dr. Myron W. Wentz, Founder & Chairman (Age 77)
  • Mr. Kevin G. Guest, CEO & Director (Age 55)
  • Mr. Jim Brown, Pres & COO (Age 49)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 48)
  • Mr. Daniel A. Macuga Jr., Chief Communications & Marketing Officer (Age 48)

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (8.75%), Vanguard Group Inc. (5.20%), BlackRock Inc. (4.44%), Acadian Asset Management LLC (3.62%), Dimensional Fund Advisors LP (2.97%) and Prudential Financial Inc. (1.18%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

Which major investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, FMR LLC, Morgan Stanley, Schroder Investment Management Group, Hsbc Holdings PLC, Acadian Asset Management LLC, Dimensional Fund Advisors LP and GSA Capital Partners LLP. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

Which major investors are buying USANA Health Sciences stock?

USNA stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Vanguard Group Inc., BlackRock Inc., Robeco Institutional Asset Management B.V., Robeco Institutional Asset Management B.V., Sensato Investors LLC, AQR Capital Management LLC and SG Americas Securities LLC. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull and Myron W Wentz. View Insider Buying and Selling for USANA Health Sciences.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $124.41.

How big of a company is USANA Health Sciences?

USANA Health Sciences has a market capitalization of $2.88 billion and generates $1.05 billion in revenue each year. The company earns $62.53 million in net income (profit) each year or $4.06 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is http://www.usana.com.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]


MarketBeat Community Rating for USANA Health Sciences (NYSE USNA)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  343 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about USANA Health Sciences and other stocks. Vote "Outperform" if you believe USNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel